12/11/2023 0 Comments Oxygen xml editor![]() The current annotation count on this page is being calculated. Recovery efforts should monitor access to screening and early diagnosis to determine if prevention services need strengthening to increase coverage of disadvantaged groups and reduce disparities. Extent of COVID-19-induced reduction in breast screening participation volume differed by region and data suggested potential differences by healthcare setting (e.g., national health insurance vs private health care). Almost all studies had high risk-of-bias due to insufficient statistical analysis and confounding factors. ![]() Within the USA, population participation volumes varied ranging from +18% to -39% with suggestion of differences by insurance status (HMO, Medicare, and low-income programs). Among two countries with limited population-based programs the decline ranged from -61% to -41%. Changes in screening participation volume in five countries with national population-based screening ranged from -13% to –31%. Reductions in screening volume and uptake rates were observed among eight countries. Twenty-six cross-sectional descriptive studies (focusing on 13 countries) were included out of 935 independent records. To assess for risk-of-bias, we used the Joanna Briggs Institute Critical Appraisal tool. We extracted and analyzed data regarding study methodology, screening volume and uptake. Studies covering January 2020 to March 2022 were included. We systematically searched Medline, the WHO (World Health Organization) COVID-19 database, and governmental databases. As the pandemic has affected countries differently, we aimed to quantify changes in breast screening volume and uptake during the first year of COVID-19 crisis. COVID-19 has strained population breast mammography screening programs that aim to diagnose and treat breast cancers earlier.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |